Status:
TERMINATED
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.
Lead Sponsor:
Melbourne Health
Conditions:
Renal Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have ...
Detailed Description
The study hypothesis is that when used as an anticoagulant in haemofiltration, fondaparinux prolongs the filter life when compared to enoxaparin. Fondaparinux is the first compound of a new class of ...
Eligibility Criteria
Inclusion
- Adult patients (18 years or over) admitted to the ICU and expected to stay for more than 48 hours.
- Patients who require continuous renal replacement therapy.
- Patients who consent or if the patient is not competent, the next of kin who consent to inclusion in the study. .
- \-
Exclusion
- Patients aged less than 18 years of age.
- Patients who are pregnant
- Patients with a contraindication to anticoagulation for pre existing bleeding diathesis
- Patients or next of kin who do not consent to study inclusion. -
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00256100
Start Date
June 1 2004
End Date
December 1 2007
Last Update
April 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Melbourne Hospital Intensive Care Unit Grattan Street
Parkville, Victoria, Australia, 3050